Objectives: To identify key oncogenes and proteins that are controlled by the microRNA miR-29 family (miR-29a, miR-29b and miR-29c) in renal cell carcinoma pathogenesis. Methods: Genome-wide gene expression and in silico database analyses were carried out. The Cancer Genome Atlas database was used to investigate the clinical significance of gene expression data in renal cell carcinoma patients. Loss-of-function assays were applied to investigate the function of target genes. Results: We identified 47 possible target genes that might be regulated by the miR-29 family in renal cell carcinoma cells. Among the targets of the miR-29 family, high expression of 10 genes (ADAMTS14, TRIB13, SERPINH1, FCGR1B, COL1A1, LAIR2, WISP2, TREM1, TNKS1BP1 and GBP2) significantly predicted poor patient prognosis (P < 0.001). SERPINH1 was directly regulated by the miR-29 family, and its overexpression was detected in renal cell carcinoma surgical specimens and tyrosine kinase inhibitor failure autopsy specimens. High expression of SERPINH1 was significantly associated with tumor stage, pathological grade and poor prognosis (P < 0.0001). Knockdown assays showed that its expression enhanced cancer cell migration and invasive abilities. Conclusions: Genes regulated by the anti-tumor miR-29 family are closely involved in the molecular pathogenesis of renal cell carcinoma. Our approach based on anti-tumor microRNAs might contribute to the development of new diagnostic markers and therapeutic strategies.
Introduction
RCC is a common neoplasm, ranking 9th and 14th overall in men and women, respectively. 1 It is also the most common malignant neoplasm in adult kidneys. ccRCC is the most common subtype (approximately 70-80%) of RCC.
2 Approximately 25-30% of patients are found with metastases at the time of diagnosis. 2 For metastatic RCC, VEGF-targeted therapy is generally used as a first-line treatment, but it is difficult to achieve a complete response, and treatment resistance and recurrence occur in many cases. 3 Thus, early diagnostic systems and new treatment strategies are important for improvements in RCC prognosis. Currently, there are no useful biomarkers for early detection or recurrence of RCC.
miRNA is a single-stranded RNA molecule 19-23 bases in length. miRNAs are involved in post-transcriptional regulation of gene expression in eukaryotes. miRNAs bind to their target mRNAs, generally recognizing the UTR of the target genes and destabilizing the molecule, thereby suppressing their translation. 4 Interestingly, a single miRNA species might regulate a vast number of protein-coding and non-coding RNAs. 5 In cancer cells, aberrantly expressed miRNAs trigger the failure of orderly and controlled RNA networks. Dysregulated RNA networks contribute to cancer cell development, metastasis and drug resistance. 6 Finding aberrant miRNAs in cancer cells is a first step in miRNA cancer research.
Based on our original miRNA expression signatures, including that for RCC, we have identified RNA networks that are controlled by anti-tumor miRNAs in several cancers. [7] [8] [9] Downregulation of the miR-29 family (miR-29a, miR-29b and miR-29c) was frequently observed in many types of cancers. 10 The miR-29 family consists of four miRNAs that are located in two chromosomal region, miR29a/miR-29b-1 at 7q32 and miR-29c/miR-29b-2 at 1q32. 11 Interestingly, c-MYC binds to the promoter region of miR29a/miR-29b-1 and inhibits its expression. Activation and overexpression of c-MYC has been reported in many cancers. 12 Furthermore, TGF-beta inhibits the expression of the miR-29 family and promotes the expression of ECM components. 13 Analyses of RNA networks regulated by the miR-29 family will contribute to our understanding of cancer pathogenesis. We have identified several targets regulated by the miR-29 family in RCC, cervical cancer, prostate cancer, lung cancer, and head and neck cancer. [14] [15] [16] [17] Our previous studies showed that LOXL2 was a direct target of the miR-29 family and its overexpression was detected in several cancers, including RCC. 17 A LOXL2 inhibitor has been developed and it showed anti-tumor inhibitory effects. 18 Searching for anti-tumor miRNA targets will contribute to understanding the molecular pathology of RCC. These targets will lead to the development of early detection markers of RCC and new therapeutic drugs. Here, we identified oncogenes that are involved in RCC pathogenesis and were controlled by the anti-tumor miR-29 family.
Methods

Identification of candidate genes regulated by the miR-29 family in RCC cells
We used in silico and genome-wide gene expression analyses. Genes regulated by the miR-29 family were detected using the TargetScan database (release 7.1). Oligo microarrays (Human GE 60K; Agilent Technologies, Santa Clara, CA, USA) were used for gene expression analyses. The microarray data were deposited into GEO (accession number: GSE66498). To determine upregulated genes in RCC cells, we analyzed publicly available gene expression datasets in GEO (accession number: GSE36895). We tried to identify gene set signatures, "a microRNA-29 regulation gene set".
Clinical database analysis
The clinical significance of target genes in RCC was investigated with TCGA database (https://tcga-data.nci.nih.gov/tcga/). The gene expression and clinical data were retrieved from cBioportal (http://www.cbioportal.org/) and OncoLnc (data downloaded on 7 January 2018). [19] [20] [21] The Genomics Analysis and Visualization Platform was used for construction of gene expression heatmaps and clustering. 22 The normalized mRNA expression values in the RNA sequencing data were processed and provided as Z-scores. In the present study, patients were divided into two groups: Z-score ≥0 and Z-score <0.
Human tissue samples, cell lines and cell culture RCC and normal tissues (17 pairs) were obtained from patients who underwent radical nephrectomy at Chiba University Hospital between 2014 and 2015 (Table 1) . We also collected tissues from three patients who died of ccRCC after TKI treatment (2012-2016) and who underwent autopsy at Teikyo University Chiba Medical Center Hospital, Chiba, Japan (Table S1 ). All patients in the present study provided informed consent for the use of their tissues for scientific research. The protocol for this study was approved by the institutional review board of Chiba University and Teikyo University.
In the present study, we used two human RCC cell lines, 786-O and A498. Both cell lines were obtained from the American Type Culture Collection. 8, 23 The cells stocks were immediately made and were used within 3 months. The quality of cells should be fine in the study. T1a  a  0  0  eg  1  0  0  0  0  2  59  Male  G3 > G2  T1b  a  0  0  eg  1  0  0  0  0  3  79  Male  G2 > G3 > G1  T1a  a  0  0  eg  1  0  0  0  0  4  81  Male  G1 > G2  T1b  a  0  0  eg  1  0  0  0  0  5  52  Male  G2 > G3  T1b  a  0  0  eg  1  1  0  0  0  6  64  Male  G2 > G3 > G1  T3a  b  1  0  ig  0  1  1  0  0  7  71  Male  G2 > G1 > G3  T1a  a  1  0  eg  1  0  0  1  0  8  67  Male  G2 > G3 > G1  T3a  b  1  0  ig  1  0  0  0  0  9  60  Female  G1 > G2 > G3  T1b  b  1  0  ig  0  0  0  0  0  10  77  Male  G1 > G2  T1b  a  0  0  eg  1  0  0  0  0  11  77  Male  G2 > G1  T3a  a  1  0  eg  1  0  0  0  0  12  62  Male  G2 > G3  T3a  b  0  0  ig  0  0  1  0  0  13  66  Male  G2 > G1  T1a  a  0  0  eg  0  0  0  0  0  14  51  Female  G2 > G1 > G3  T3a  b  1  0  ig  0  0  0  0  0  15  57  Male  G1 > G2  T1a  a  0  0  eg  1  0  0  0  0  16 The following molecular reagents were used: mature miRNAs, Pre-miR miRNA precursors (hsa-miR-29a-3p, assay ID:
MC12499; hsa-miR-29b-3p, assay ID: MC10103; hsa-miR29c-3p, assay ID: MC10518; Applied Biosystems, Foster City, CA, USA), negative control miRNA (assay ID: AM17111; Applied Biosystems) and siRNA (Stealth Select RNAi siRNA; si-SERPINH1 P/N: HSS101423 and HSS189522; Invitrogen, Carlsbad, CA, USA). The transfection procedures were described previously.
8,23
qRT-PCR
The procedures for qRT-PCR quantification were outlined. 8, 23 TaqMan probes and primers for SERPINH1 (P/N: Hs01060397; Thermo Fisher Scientific, Waltham, MA, USA), GXYLT2 (P/N: Hs01109143), KDELC1 (P/N: Hs00985767) and LOXL2 (P/N: Hs00158757) were assay-on-demand gene expression products.
To normalize the data, we used human GUSB (P/N: Hs999999 08_m1; Applied Biosystems) and RNU48 (assay ID: 001006; Applied Biosystems).
Immunohistochemistry
We used tissue microarray for primary ccRCC (cat. no. KD806; US Biomax, Rockville, MD, USA) and autopsy specimens after TKI treatment. Patient characteristics for samples used in the tissue microarray are described in http:// www.biomax.us/tissue-arrays/Kidney/KD806. Tissue samples were incubated overnight at 4°C with anti-SERPINH1 antibodies diluted 1:50 (sc-5293; Santa Cruz Biotechnology, Santa Cruz, CA, USA). The procedures for western blot analysis were described.
8,23
Western blot analysis
Antibodies used in this experiment were mouse monoclonal anti-SERPINH1 antibodies (1:200 dilution; sc-5293; Santa
Cruz Biotechnology). Anti-GAPDH antibodies (1:1000 dilution; ab8245; Abcam, Cambridge, UK) were used as an internal control. The procedures for western blot analysis have been previously described.
Plasmid construction and dual-luciferase reporter assay
The recombinant vectors were constructed with wild-type or mutant sequences that were inserted between the SgfI-PmeI restriction sites in the 3 0 -UTR of the hRluc gene in the psi-CHECK-2 vector (C8021; Promega, Madison, WI, USA). 786-O cells were seeded into 24-well plates and co-transfected with 20 nmol/L microRNAs and 20 ng of the vector, using 1 lL Lipofectamine 2000 (Invitrogen) in 100 lL Opti-MEM (Invitrogen). After transfecting for 24 h, firefly and Renilla luciferase activities were measured consecutively with a Dual-Luciferase Reporter Assay system. Renilla luciferase intensity (Renilla/firefly) was used as normalized data. The luciferase reporter assay was carried out as previously described.
Regulation of targets downstream of SERPINH1 in RCC cells
We investigated pathways regulated by SERPINH1 in RCC cells. We analyzed gene expression using si-SERPINH1-transfected 786-O cells. Microarray data were used for expression profiling of si-SERPINH1 transfectants. The microarray data were deposited into GEO (accession number: GSE113066). (Table 2) Candidate target genes by miR-29 family regulation in RCC cells 
Cell proliferation, migration and invasion assays
The procedures for assessment of cell proliferation, migration and invasion were described previously.
8,23
Statistical analysis
Bonferroni-adjusted Mann-Whitney U-tests were used to analyze the differences among more than three groups. Statistical tests were carried out using Expert StatView software (version 5.0; SAS Institute, Cary, NC, USA). Survival analysis was carried out using the Kaplan-Meier method, log-rank tests and multivariable Cox hazard regression analyses with JMP software (version 13; SAS Institute).
Results
Identification of oncogene sets regulated by the miR-29 family in RCC cells
First, to investigate miR-29a targets gene in RCC cells, we carried out a genome-wide gene expression study. 17 Expression data were deposited in the GEO database (accession number: GSE66498). As a result, we found a total of 424 genes were downregulated in miR-29 family transfected RCC cells (log 2 ratio <À1.5). Next, we merged the gene expression data of ccRCC clinical specimens. In this way, we identified 47 candidate target genes of miR-29 family regulation in ccRCC cells (Table 2 ). Our selection strategy is shown in Figure 1 . We generated a heatmap of 47 genes to visualize gene expression of RCC specimens to each gene (Fig. 2) . Also, we validated the prognostic abilities of those 47 genes. We compared the DFS of the following groups, patients with high gene signature expression (Z-score ≥0) and low gene signature expression (Z-score <0). As shown in Figure 2b , patients with a high expression group had significantly lower DFS rates than those with a low expression group.
Among these 47 genes, we selected the genes whose expression status was involved in RCC pathogenesis. High expression levels of 10 genes (ADAMTS14, TRIB13, SER-PINH1, FCGR1B, COL1A1, LAIR2, WISP2, TREM1, TNKS1BP1 and GBP2) were significantly associated with lower OS rates in RCC patients (P < 0.001; Fig. 3 ). We defined those 10 genes as a gene set, and created a gene heatmap and analyzed its prognostic ability (Fig. 4a) . Patients with high gene signature expression were clearly subject to tumor recurrence and poor OS (P < 0.0001; Fig. 4b,d) . Furthermore, we carried out Cox hazard multivariate analysis LAIR2  C10ORF99  SLC7A11  TREM1  GXYLT2  TRIB3  WISP2  ADAMTS14  KDELC1  FSTL1  PDGFD  HMCN1  GJA1  LINGO1  GNG2  LAMC1  SPARC  NID1  COL4A2  COL4A1  SCG2  PTRF  EHD2  PMP22  LOXL2  SERPINH1  COL1A1  TNKS1BP1  CAV2  CAV1  AHNAK  CXCR4  CP  PAG1  IL7  GBP2  CD3G  FCGR1B  BTK  KCNMA1  EDN1  NDRG1  DIRAS2  TTYH3  GAL3ST1  ABCB6 (b) with clinical characteristics, and found that the gene signature expression was an independent prognostic factor for DFS and OS (HR 1.55, P = 0.025 and HR 1.79, P = 0.0003, respectively; Fig. 4c,e) . Interestingly, when we focused on T1b patients, the gene signature expression was also a strong predictor for DFS in RCC patients (Fig. 5) .
Our previous studies showed that aberrant expression of LOXL2 enhanced cancer cell aggressiveness in several cancers, including RCC cells. 24 The LOXL2 was directly regulated by the miR-29 family, and the function of LOXL2 is involved in cross-linking of collagen and/or elastin in the ECM. 24 The SERPINH1 (also known as HSP47) is a 47 kDa collagen-binding glycoprotein and its expression contributes to collagen biosynthesis. 25 Our recent study showed that overexpression of SERPINH1 was detected in clinical specimens of lung cancer and idiopathic pulmonary fibrosis.
16
SERPINH1 was the only gene that has a putative binding site of the miR-29 family among the set of 10 genes (Fig. 3,  Table 2 ). In the present study, we focused on SERPINH1 and to investigate the functional significance of SERPINH1 and RCC pathogenesis.
Expression of SERPINH1 protein in RCC clinical specimens and its clinical significance
The mRNA levels of SERPINH1 were significantly higher in 17 ccRCC clinical specimens than in non-cancer specimens (P = 0.0002; Fig. 6a ). Immunostaining analyses showed that SERPINH1 was more strongly expressed in primary ccRCC and autopsy specimens after TKI treatment than in tissue adjacent to ccRCC (Fig. 6b,c) .
After multivariate analysis, expression of SERPINH1 was an independent predictive factor for OS (HR 1.59, P = 0.0037; Fig. 7a ). Kaplan-Meier analysis showed that the high SERPINH1 expression group had a significantly shorter DFS period compared with the low SERPINH1 expression group (P < 0.0001; Fig. 7b ). Furthermore, there was a significant association between patients with high SERPINH1 gene expression and advanced tumor stage and pathological grade (Fig. 7c-f) . Furthermore, Spearman's rank test showed a negative correlation between the expression levels of miR-29b/SERPINH1 and miR-29c/SERPINH1 (P = 0.0129; R = À0.111, P < 0.0001; R = À0.199, respectively) by using a large number of cohort studies by TCGA datasets (Fig. S2) .
Direct regulation of SERPINH1 by the anti-tumor miR-29 family in RCC cells
We confirmed that gene expression of SERPINH1 was significantly decreased in RCC cells transfected with the miR-29 family compared with mock or miR-control RCC cell lines (P < 0.0001; Fig. 8a ). Western blotting analyses showed that SERPINH1 protein levels in RCC cells transfected with the miR-29 family were lower than mock or miR-control RCC cell lines (Fig. 8b) .
Next, we carried out luciferase reporter assays with the 786-O cell line to determine whether the miR-29 family directly targeted the 3 0 -UTR of SERPINH1. According to the TargetScan Human database, the binding site for the miR-29 family in the 3 0 -UTR of SERPINH1 consisted of a single region (position 57-63; Fig. 8c ). We showed that the miR-29 family suppressed reporter activity of cells transfected with SERPINH1 wild-type vector compared with mock or miR-control transfectants (P < 0.005; Fig. 8d ).
Effects of silencing of SERPINH1 in RCC cells
To assess the function of SERPINH1 in RCC cells, loss-offunction assays using siRNA were carried out. We evaluated Disease-free survival rate Log-rank P-value < 0.0001 Z-score < 0 (n = 284) the knockdown efficiency of si-SERPINH1-transfected RCC cell lines. Downregulation of SERPINH1/SERPINH1 was detected in si-SERINH1 transfectants (P < 0.0001; Fig. 9a,b) . Cancer cell proliferation, migration and invasive abilities were significantly reduced in si-SERPINH1 transfectants compared with those in mock or miR-control transfected RCC cell lines (Fig. 9c-e) .
Downstream genes affected by silencing of SERPINH1 in RCC cells
Finally, we investigated genome-wide gene expression analysis using si-SERPINH1 in 786-O cells to investigate which genes were mediated by SERPINH1 signaling. A SurePrint G3 Human GE 60K v3 microarray was used for genome- wide expression analysis. SERPINH1 was the most significantly downregulated gene, indicating that the array data were reliable. We identified 48 candidate genes (Table 3) and generated a gene expression heatmap of the data (Fig. 10a) .
Patients with high gene signature expressions were significantly associated with lower DFS and OS rates than those with low gene signature expression (Fig. 10b,c) .
Direct regulation by the miR-29 family and clinical significance of GXYLT2, KDELC1 and LOXL2
We further investigated three genes (GXYLT2, KDELC1 and LOXL2) that were directly regulated by the miR-29 family and were significantly associated with the prognosis of RCC patients (Table 2) . We confirmed that gene expression levels of the three genes were significantly decreased in RCC cells transfected with the miR-29 family compared with the mock or miR-control RCC cell lines. Kaplan-Meier analysis showed that the high expression group had significantly shorter DFS periods compared with the low expression group. Furthermore, patients with high expression were significantly associated with advanced tumor stage and pathological grade excluding tumor stage of LOXL2 (Fig. S1 ).
Discussion miRNAs possess a unique feature in that a single miRNA species can control a vast number of RNA transcripts. 5 Therefore, aberrantly expressed miRNAs have the ability to disrupt intracellular RNA networks. 26 A large number of studies showed that dysregulated miRNAs are involved in cancer pathogenesis. 6 From another point of view, it is possible to search oncogenic RNA networks induced in cancer cells based on aberrantly expressed miRNAs.
Analyses of miRNA expression signatures in several cancers showed that the miR-29 family was frequently downregulated in many types of cancers and that they acted as pivotal anti-tumor RNAs. 10 We have shown that the antitumor miR-29 family regulates oncogenes and pathways in cervical cancer, head and neck squamous cell carcinoma, lung cancer, and RCC. [14] [15] [16] [17] Interestingly, expression levels of miR-29 family were downregulated in sunitinib-treated RCC compared with primary RCC from our previous data. mRNA. Dual luciferase reporter assays using vectors encoding putative miR-29 family target sites (position 57-63) of the SERPINH1 3 0 -UTR for both wild-type and mutant. Normalized data were calculated as ratios of Renilla/firefly luciferase activities. **P < 0.005.
Therefore, a comprehensive understanding of RNA networks controlled by the anti-tumor miR-29 family should be an important focus of cancer research. Our recent studies showed that the ECM and its receptors were regulated by the miR-29 family, and activation of ECM-integrin signaling pathways enhanced cancer cell aggressiveness. 15 Genes involved in these pathways might be potential targets for cancer therapies. In the present study, we identified several oncogenes that are controlled by the miR-29 family, genes that are involved in RCC pathogenesis.
In RCC cells, we identified 47 genes that were putative targets of the miR-29 family. Interestingly, among these targets, high expression of the set of 10 genes (ADAMTS14, TRIB13, SERPINH1, FCGR1B, COL1A1, LAIR2, WISP2, TREM1, TNKS1BP1 and GBP2) was significantly associated with poor prognosis of RCC patients. We suggest that those genes might represent promising prognostic markers for this disease.
It is difficult for the clinical urologist to determine whether patients with T1b RCC should be subjected to total nephrectomy or partial nephrectomy. The National Comprehensive Cancer Network guidelines, version 2 (2017), presents both surgical approaches. 27 Currently, the approach is determined by tumor size and the positional relationship between the tumor and the vascular system and urinary tract. However, which surgical procedure to use is left to the clinician. The present data suggested that gene expression analyses will be involved in the prediction of the recurrence and treatment strategy of RCC. Development of the non-invasive diagnostic method is a new challenge for the RCC diagnosis strategy using gene expression signature. In order to show the effectiveness of the present data, further cohort studies and the development of a new diagnosis strategy are required in the future.
In the present study, we showed that in RCC cells, SER-PINH1 was directly regulated by the miR-29 family. Overexpression of SERPINH1 was observed in ccRCC and clinical specimens from patients who failed TKI. SERPINH1 is a member of the serpin superfamily of serine proteinase inhibitors. The protein resides in the endoplasmic reticulum and plays a role in collagen biosynthesis as a collagen-specific molecular chaperone. 25 In breast cancer, the expression of SERPINH1 correlates with the expression of collagen and fibronectin, and SERPINH1 regulates the gene network of the ECM, and is related to tumor growth and invasion. 25, 28 In idiopathic pulmonary fibrosis and lung cancer, LOXL2 and SERPINH1 are regulated by miR-29a, and these genes were overexpressed. 16 The correlation between RCC pathogenesis and SERPINH1 remains uncertain. Previous reports showed that overexpression of SERPINH1 promotes procollagen production, resulting in the development of the epithelial mesenchymal transition. 29 Recent studies suggested that aberrantly expressed ECM genes and their receptors enhanced cancer cell aggressiveness. 24, 30 Elucidation of genes modulated by SERPINH1 might provide novel therapeutic approaches in RCC.
In conclusion, genes controlled by the anti-tumor miR-29 family were closely involved in RCC pathogenesis. The gene expression signature that we successfully identified predicted poor prognosis of patients with RCC. SERPINH1 was directly regulated by the miR-29 family in RCC cells. Aberrantly expressed SERPINH1 enhanced RCC cell aggressiveness, and its expression was significantly associated with poor prognosis of the patients. Elucidation of anti-tumor miRNAs controlling RNA networks might provide novel prognostic markers and therapeutic targets for this disease.
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